View Older Stories View More Recent Stories

Jan 23, 2019 08:00AM Government Employees Affected by Federal Shutdown Encouraged to Contact Lilly Diabetes Solution Center to Access Insulin
Jan 7, 2019 10:00AM Bigfoot Biomedical Announces Next Step for Connected Insulin Injection System
Dec 14, 2018 06:46AM Eli Lilly & Co. (LLY) Announces Expanded Collaboration with Evidation Health to Analyze Data from Smartphones & Connected Sensors
Dec 14, 2018 06:45AM Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors
Dec 13, 2018 06:48AM Lilly (LLY) and Incyte (INCY) Announce FDA Granted Fast Track Designation to Baricitinib Development Program for Treatment of SLE
Dec 13, 2018 06:45AM FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
Dec 13, 2018 06:30AM Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
Dec 3, 2018 10:15AM NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment
Nov 26, 2018 02:36PM Lilly (LLY) Reports Jardiance Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in ACC Expert Consensus Decision Pathway
Nov 26, 2018 02:34PM Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
Nov 5, 2018 06:46AM Lilly (LLY) says Trulicity demonstrates superiority in reduction of cardiovascular events for people with type 2 diabetes
Nov 5, 2018 06:45AM Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes
Nov 5, 2018 06:37AM Lilly (LLY) says Initial results from EMPRISE real-world evidence study show Jardiance was associated with reduced risk for HHF
Nov 5, 2018 06:30AM Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diab
Oct 24, 2018 05:51AM Pfizer (PFE), Eli Lilly and Co. (LLY) Report Complete Results from Phase 3 Study of Tanezumab Showing Significant Improvement in Pain & Function in Osteoarthritis Patients
Oct 23, 2018 06:40PM Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients
Oct 21, 2018 06:30PM ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis
Oct 17, 2018 09:01AM Express Scripts (ESRX) Announces New Value-Based Program for Migraine
Oct 10, 2018 06:34AM Boehringer Ingelheim and Eli Lilly (LLY) say new analysis estimates positive impact of Jardiance on life expectancy
Oct 10, 2018 06:30AM New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease
Oct 4, 2018 11:17AM Boehringer Ingelheim, Lilly (LLY) present full results of Tradjenta's CARMELINA cardiovascular outcome trial
Oct 4, 2018 11:15AM Boehringer Ingelheim and Lilly present full results of Tradjenta®'s CARMELINA® cardiovascular outcome trial
Oct 4, 2018 06:32AM Eli Lilly & Co. (LLY), Boehringer Ingelheim Announce Empagliflozin Met Primary Efficacy Endpoint in EASE Phase III program
Oct 4, 2018 06:30AM Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
Oct 4, 2018 06:04AM Eli Lilly & Co. (LLY) Reports Data from Investigational Dual GIP & GLP-1 Receptor Agonist Showing Significant Reduction in HbA1c & Body Weight
Oct 4, 2018 06:00AM Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
Oct 2, 2018 06:02AM Eli Lilly & Co. (LLY) Reports Data from Two Phase 3 Studies Showing Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 & Type 2 Diabetes
Oct 2, 2018 06:00AM Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes
Sep 26, 2018 07:00PM Chugai and Lilly Enter into a License Agreement for Oral GLP-1 Agonist, OWL833
Sep 19, 2018 07:07PM GREATERGOOD.ORG JOINS FORCES WITH ELANCO ANIMAL HEALTH TO MEET CRITICAL HEALTH NEEDS TO HELP THOUSANDS OF PETS AFFECTED BY HURRICANE FLORENCE
Sep 12, 2018 09:05AM NCCN and Lilly Support Quality Improvements for Gastric Cancer Care
Aug 1, 2018 09:00AM Lilly Diabetes Solution Center Now Open to Help People with Insulin Affordability
Jul 24, 2018 07:32AM S&P reaches highest level since February as Alphabet shares soar
Jul 19, 2018 06:30PM Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)
Jul 19, 2018 08:05AM BI, Lilly Announce Tradjenta's CARMELINA Cardiovascular Outcome trial Meets Primary Endpoint
Jul 19, 2018 08:00AM Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint
Jul 19, 2018 06:47AM Lilly (LLY) Once-Weekly Trulicity Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and CKD
Jul 19, 2018 06:45AM Lilly's Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease
Jul 18, 2018 06:48AM Pfizer (PFE), Eli Lilly (LLY) Reports Positive Top-Line Results from Phase 3 Trial Of Tanezumab for Treatment of Osteoarthritis Pain
Jul 18, 2018 06:45AM Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
Jul 12, 2018 06:45AM New Lilly Diabetes helpline to Assist People Seeking Solutions to Insulin Affordability
Jun 25, 2018 08:06AM Boehringer Ingelheim, Lilly (LLY) Announce Phase III for Empagliflozin as Adjunct to Insulin in Type 1 Diabetes Met Primary Endpoint
Jun 25, 2018 08:00AM First-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes
Jun 25, 2018 08:00AM Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
Jun 25, 2018 06:03AM Eli Lilly & Co. (LLY) and Boehringer Ingelheim Announce Update from Two New Analyses from EMPA-REG OUTCOME Trial,
Jun 25, 2018 06:01AM Eli Lilly & Co. (LLY) Highlights New Data from Three Phase 1b Studies Evaluating URLi Compared to Humalog
Jun 25, 2018 05:56AM Eli Lilly & Co. (LLY) Highlights Promise of Once-Weekly Trulicity (dulaglutide) in Data from Phase 2 study
Jun 24, 2018 09:00AM Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW
Jun 23, 2018 10:00AM New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce Potential of Lilly's Ultra Rapid Lispro in People with Type 1 and Type 2 Diabetes
Jun 23, 2018 10:00AM Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
View More Recent Stories View Older Stories